TL;DR
This paper reveals that adapting to one antibiotic can surprisingly make bacteria more sensitive to others (collateral sensitivity), a phenomenon that occurs frequently. Specifically, E. coli evolving resistance to aminoglycosides become hypersensitive to a range of other antibiotics due to mutations that disrupt their proton-motive force, indirectly impairing drug efflux pumps. This finding offers new perspectives on antibiotic resistance evolution and potential therapeutic strategies.
What Problem Does This Paper Address?
The evolution of antibiotic resistance is a major global health concern. While it's well-established that resistance to one drug can sometimes confer resistance to others (cross-resistance), the opposite phenomenon – collateral sensitivity, where adaptation to one antibiotic increases sensitivity to others – is much less understood. The frequency, underlying mechanisms, and evolutionary implications of collateral sensitivity are largely unknown. This paper aims to systematically investigate these questions using E. coli as a model system, seeking to understand how genetic adaptation to antibiotic stress can lead to these unexpected trade-offs.
Methods
The researchers employed a multi-pronged approach:
- Large-Scale Laboratory Evolution: They evolved E. coli populations under two distinct antibiotic selection regimes:
- Constant Sublethal Concentration: Populations were maintained for ~140 generations in the presence of a fixed, low concentration of one of 24 different antibiotics.
- Gradually Increasing Concentration: For a subset of 12 antibiotics, populations were evolved over 240-384 generations, with the antibiotic concentration progressively increased.
- Systematic Susceptibility Profiling: Each evolved bacterial line was then tested for its sensitivity to all other antibiotics used in the study. This allowed them to map out "collateral-sensitivity networks."
- Whole-Genome Resequencing: To identify the genetic basis of resistance and collateral sensitivity, the genomes of selected evolved strains were sequenced.
- Biochemical Assays: To probe the functional consequences of identified mutations, they performed assays to measure membrane potential and cellular permeability (using Hoechst dye accumulation).
- Genetic Manipulation: They created specific mutant strains (e.g., by deleting or overexpressing the AcrAB efflux pump genes) to directly test hypotheses about the role of specific molecular mechanisms.
Datasets
The study utilized Escherichia coli K12 (BW25113) as the model organism. The primary "dataset" generated was the comprehensive map of collateral-sensitivity interactions derived from the laboratory evolution experiments and subsequent phenotypic profiling. They also leveraged existing chemogenomic data from previous studies to compare their findings. No new public benchmarks were introduced, but the study generated a novel, extensive dataset of collateral-sensitivity interactions.
Key Insights and Ideas
- Collateral Sensitivity is Frequent: Contrary to the common focus on cross-resistance, this study demonstrates that collateral sensitivity is a prevalent outcome of antibiotic adaptation.
- Aminoglycosides are Key Players: Adaptation to aminoglycoside antibiotics disproportionately drives collateral sensitivity, making bacteria hypersensitive to a wide array of other drug classes.
- Proton-Motive Force (PMF) is Central: Mutations that reduce the PMF across the inner bacterial membrane are a common mechanism for aminoglycoside resistance and, critically, are linked to hypersensitivity to other antibiotics.
- Efflux Pumps are Indirectly Affected: The reduced PMF, a consequence of aminoglycoside resistance mutations, appears to impair the function of PMF-dependent multidrug efflux pumps (like AcrAB), leading to increased intracellular accumulation of other antibiotics.
- Negative Trade-offs Drive Evolution: The findings highlight that evolutionary adaptation is not always a simple gain of function; it often involves complex trade-offs, where improving fitness in one context can lead to a fitness cost in another.
Key Results
- Dense Collateral Sensitivity Network: The study mapped a "strikingly dense network" of collateral-sensitivity interactions, with at least 35% of all investigated antibiotic pairs showing this phenomenon in at least one direction.
- Aminoglycoside Dominance: 44% of all collateral-sensitivity interactions involved aminoglycosides, which frequently led to 2- to 10-fold decreases in the Minimum Inhibitory Concentrations (MICs) for other antibiotics.
- PMF-Related Mutations: Whole-genome sequencing identified mutations in genes involved in maintaining the membrane electrochemical potential (e.g., trkH, cyoB, ispA, nuo genes) in a significant proportion of aminoglycoside-resistant strains.
- Single Mutation Impact: A specific mutation in trkH was shown to confer mild aminoglycoside resistance while simultaneously increasing susceptibility to non-aminoglycoside antibiotics, reducing membrane potential, and enhancing Hoechst dye accumulation.
- AcrAB Efflux System Link: The study provided strong evidence that the AcrAB efflux system plays a key role, as mutations diminishing PMF reduced the resistance conferred by AcrAB overexpression to various non-aminoglycoside antibiotics.
Limitations and Future Work
- Unexplained Interactions: The authors acknowledge that a substantial fraction of collateral-sensitivity interactions, particularly those unrelated to aminoglycosides, require further mechanistic explanation.
- Horizontal Gene Transfer Ignored: The study focused on mutational adaptation and did not investigate resistance evolution via horizontal gene transfer.
- Clinical Relevance of PMF Mutations: The frequency of PMF-altering mutations in clinical isolates is largely unknown, limiting direct therapeutic implications at this stage.
- Future Directions: The authors suggest exploring the conservation of these networks across different bacterial species and investigating the role of specific genes like fusA in collateral sensitivity. They also propose that understanding these antagonistic pleiotropic effects could inform strategies for antibiotic rotation or combination therapy.
Summary updated